A real-world study on the efficacy and safety of low-dose PD-1 monoclonal antibody alone or in combination as the first-line treatment for advanced non-small cell lung cancer

A real-world study on the efficacy and safety of low-dose PD-1 monoclonal antibody alone or in combination as the first-line treatment for advanced non-small cell lung cancer

Background In clinical practice, patients with non-small cell lung cancer (NSCLC) often receive low-dose programmed death-1 (PD-1) monoclonal antibodies due to physical or financial limitations. However, the efficacy and safety of low-dose compared with standard-dose PD-1 monoclonal antibodies remai...

Full description

Saved in:
Bibliographic Details
Main Authors: Tao Han, Xin Li, Lu Xu, Jingqi Sun, Junli Hao, Sha Shi, Heming Li, Mingfang Zhao
Format: Article
Language:English
Published: BMJ Publishing Group 2025-06-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/13/6/e011622.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items